isoquercetin

Drug Overview

Isoquercetin is a highly specialized, investigational medication currently being studied in modern cancer care. It is a naturally occurring plant compound, known as a flavonoid, that has been scientifically modified so the human body can absorb it more easily. In oncology, isoquercetin acts as a Targeted Therapy. Unlike traditional chemotherapy that attacks all fast-growing cells, it is designed to target specific enzymes in the body to help prevent dangerous blood clots in cancer patients and to slow down tumor growth.

• Generic Name: Isoquercetin (also referred to as quercetin-3-O-glucoside or isoquercitrin).
• US Brand Names: Kinisoquin™ (currently an investigational drug used in clinical trials).
• Drug Class: Flavonoid / Protein Disulfide Isomerase (PDI) Inhibitor / Targeted Therapy.
• Route of Administration: Oral (taken by mouth as a pill or capsule).
• FDA Approval Status: Currently investigational. It is not yet FDA-approved for standard public clinical use but is actively being evaluated in advanced Phase II and Phase III clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Isoquercetin is a Targeted Therapy designed to work at the microscopic, molecular level to solve two major problems in cancer: the high risk of blood clots and the growth of tumor cells.

When a person has advanced cancer, the body often produces too much of a specific enzyme called Protein Disulfide Isomerase (PDI). This enzyme acts like a chemical switch that turns on blood platelets and starts a chain reaction, leading to blood clots. These clots, known as venous thromboembolism (VTE), can be life-threatening for cancer patients. Isoquercetin works specifically as a “PDI inhibitor.” Once it enters the bloodstream, it finds the PDI enzyme and blocks its chemical signals. By turning off this enzyme, isoquercetin stops platelets from clumping together and prevents dangerous blood clots from forming.

Beyond stopping blood clots, isoquercetin also attacks cancer cells directly. It interrupts specific communication pathways inside the tumor cells, such as the Wnt/beta-catenin, IGF1R, and AKT/mTOR signaling pathways. By blocking these signals, the drug stops the cancer cells from multiplying. It also triggers a process called “apoptosis.” Apoptosis is the body’s natural way of telling damaged or cancerous cells to self-destruct. Because isoquercetin specifically targets these disease enzymes and pathways, it acts as a “smart drug,” minimizing harm to healthy, normal cells.

FDA-Approved Clinical Indications

Because isoquercetin is an investigational drug, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in major, approved clinical trials for the following purposes:

Oncological Uses (In Clinical Trials):

• Blood Clot Prevention: Used to reduce the risk of venous thromboembolism (VTE) in patients with metastatic pancreatic, ovarian, colorectal, and non-small cell lung cancers.
• Tumor Suppression: Studied for its ability to slow tumor growth in esophageal, colon, and kidney cancers by blocking key cancer cell growth pathways.
• Cancer Fatigue Management: Used alongside standard targeted therapies (such as sunitinib for kidney cancer) to reduce severe, treatment-related fatigue.

Non-oncological Uses (In Clinical Trials):

• General Anti-inflammatory Uses: Investigated for its ability to reduce general inflammation and oxidative stress in the body.
• Antioxidant Protection: Studied for its protective effects against cellular damage caused by free radicals in the bloodstream.

Dosage and Administration Protocols

Because isoquercetin is an investigational oral medication, its dosing depends entirely on the specific clinical trial protocol the patient is enrolled in. The table below outlines standard dosages used in recent research.

Clinical Efficacy and Research Results

Recent clinical studies conducted between 2020 and 2025 highlight the powerful effects of isoquercetin, particularly as a Targeted Therapy for symptom management and blood clot prevention.

• Reducing Blood Clot Risks: In recent Phase II trials for advanced cancer patients, those taking 1000 mg of isoquercetin daily saw their D-dimer levels (a key blood marker for clotting) drop by a median of 21.9%. Additionally, the drug successfully increased PDI enzyme blocking activity by 73.3% and reduced platelet-dependent clot generation by 57.2%. During these trials, no major hemorrhages or primary blood clot events were observed.
• Improving Quality of Life: In kidney cancer trials, patients taking isoquercetin alongside standard cancer treatments experienced a significant improvement in severe fatigue. Patients reported a 6.8-point improvement in clinical fatigue scores, allowing them to better tolerate their primary cancer treatments.
• Tumor Control: Laboratory and animal studies show that isoquercetin can reduce the number of blood vessels feeding colon tumors by approximately 65%, outperforming some standard treatments in cutting off the tumor’s blood supply.

Safety Profile and Side Effects

Isoquercetin is generally very well-tolerated because it is derived from a natural plant compound that selectively targets disease pathways, leaving healthy cells mostly unharmed.

Black Box Warning: There is no FDA Black Box Warning for this investigational agent.

Common Side Effects (>10%):

• Mild Stomach Upset: Some patients report mild nausea or slight digestive changes when taking the oral capsules.
• Fatigue: Mild tiredness may occur initially, even though the drug is often used long-term to treat cancer-related fatigue.

Serious Adverse Events:

• Teratogenic Effects (Harm to Unborn Baby): Because the drug blocks important cell-building enzymes (like PDI), there is a severe risk that it could harm a developing fetus or cause a miscarriage.
• Bleeding Risks: While it effectively prevents blood clots, there is a theoretical risk of increased bleeding. However, major bleeding events have been extremely rare in clinical trials.

Management Strategies:

• If mild stomach upset occurs, taking the medication with a small amount of food or adjusting the time of day it is taken can help soothe the stomach.
• If signs of bleeding occur (such as unusual bruising or bleeding gums), patients must notify their medical team immediately. The doctor may pause the medication to ensure blood clotting levels return to a safe, normal range.

Connection to Stem Cell and Regenerative Medicine

Currently, research into isoquercetin is highly focused on its role as a Targeted Therapy for tumor suppression and blood clot prevention. While flavonoids like isoquercetin are widely known to support general cellular health and reduce oxidative stress, there is no direct, major clinical focus combining this specific drug with stem cell transplants or advanced regenerative medicine therapies at this time. Its primary intersection with cellular therapy lies in its potential to modulate the immune system and improve the environment around the tumor.

Patient Management and Practical Recommendations

To ensure safety and gather the most accurate clinical trial data, patients must follow strict guidelines before and during their treatment with isoquercetin.

Pre-treatment Tests to be Performed:

• Pregnancy Test: A negative blood pregnancy test is strictly required for women of childbearing age, as the drug may cause serious harm to an unborn baby.
• Blood Panel: Doctors will check platelet counts, blood clotting times (PT/PTT), and liver function (bilirubin levels) to ensure the patient is not at a high risk for bleeding.

Precautions During Treatment:

• Women of childbearing age and men with female partners must use highly effective birth control before and during the entire trial.
• Breastfeeding must be completely stopped, as the drug could pass into breast milk and negatively affect a nursing infant.

“Do’s and Don’ts” List:

• DO take your medication at the same time every day to keep a steady amount of the drug in your system.
• DO inform your doctor about any other daily vitamins, herbal supplements, or teas you consume, as they could interact with the trial drug.
• DON’T become pregnant or nurse a baby while taking this medication.
• DON’T take over-the-counter blood thinners (like aspirin or ibuprofen) unless explicitly approved by your trial oncologist, as this could dangerously increase your risk of bleeding.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Isoquercetin (including brands like Kinisoquin™) is an investigational diagnostic and therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, and eligibility for clinical trials.